Author

Franciscary Pi-Estopiñán

Observed names: Estopiñán, Franciscary Pi, Franciscary Pi, Franciscary Pi-Estopiñan, Pi Estopiñán, Franciscary

Institutions: Center of Molecular Immunology (Cuba), Escuela Nacional de Sanidad, National School of Public Health

Observed institutions: Center of Molecular Immunology (Cuba), Escuela Nacional de Sanidad, National School of Public Health

ORCID: 0000-0002-6407-3327

Observed ORCID: 0000-0002-6407-3327

OpenAlex ID: A5024603356

SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies

2021 · Yury Valdes-Balbin, Darielys Santana-Mederos, et al. · ACS Chemical Biology · 85

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 38

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

2022 · Sonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, et al. · Vaccine · 37

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 33

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 31

Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens

2023 · Tammy Boggiano-Ayo, Julio Palacios-Oliva, et al. · Frontiers in Bioengineering and Biotechnology · 10

A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies

2022 · Franciscary Pi-Estopiñan, María Teresa Pérez, et al. · Vaccine · 10

Evaluación preclínica y clínica de SOBERANA® 01. Candidato vacunal contra la COVID-19

2023 · Climent Ruiz, Yanet, Santana Mederos, Darielys, et al. · Anales de la Academia de Ciencias de Cuba

Diseño, desarrollo y evaluación preclínica de SOBERANA®02: una vacuna cubana contra COVID-19

2023 · Balbín, Yury Valdés, Mederos, Darielys Santana, et al. · Anales de la Academia de Ciencias de Cuba

Works count: 9

Citation count: 244

H-index: 7

I10-index: 7